NewcelX Ltd Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $0TTM through 31 Dec 2025
Net Income -$8.3MTTM through 31 Dec 2025
Free Cash Flow -$2.8MTTM through 31 Dec 2025
Margins
| Current |
|---|
Returns
-114.5%ROE
-72.5%ROA
Balance Sheet Health
Debt / Equity0.05x
Current Ratio0.76x
Net Debt-$1.8Mnet cash position
Cash & Equivalents$2.2M
Quality Metrics
Altman Z-Score-8.72
Piotroski F-Score3 / 9
Multi-Year Trend
Diluted EPS-$2.16TTMFY2025: $-2.16
Dividend
No dividend
Capital Allocation
R&D Spend$1.1M
Segment Performance
No segment data available.
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.